Navigation Links
ATS Medical Announces First Quarter 2009 Earnings Release Date and Conference Call
Date:4/23/2009

MINNEAPOLIS, April 23 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced that it will release financial results for the first quarter ended April 4, 2009, after the market close on Monday, May 4, 2009. The Company will host a conference call and webcast on Monday, May 4, 2009 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss its first quarter results and current corporate developments. The dial-in number for the conference call is 866-700-0133 for domestic participants and 617-213-8831 for international participants, with a passcode of 84428361. A live webcast of the call can be accessed at www.atsmedical.com by clicking on the Investors icon.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will remain available for seven days. The replay can be accessed by dialing 888-286-8010 for domestic participants and 617-801-6888 for international participants, using the passcode 61517420. The webcast will also be archived on the Company's website.

About ATS Medical

ATS Medical, Inc. is dedicated to 'Advancing The Standards' of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.

ATS was originally founded to develop the ATS Open Pivot(R) Heart Valve as a new mechanical heart valve standard of care. Today the Open Pivot heart valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f(R) brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive, sutureless based procedures. The ATS 3f(R) portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus(R) annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze(TM) products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is http://www.atsmedical.com.


'/>"/>
SOURCE ATS Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... NY (PRWEB) , ... January 17, 2017 , ... ... Magazine’s fastest-growing private companies and ranked among the top US security companies for ... of Directors. This announcement brings a year-long independent board nomination process to ...
(Date:1/17/2017)... ... , ... Today, FloSports , a global leader in live digital sports ... of a long-term extension of their media partnership. The partnership, which began in 2013, ... sport’s premier events exclusively on FloWrestling.com as well as usage of the FloArena meet ...
(Date:1/16/2017)... ... January 17, 2017 , ... To provide ... recognized leader in the fast-casual category, announces a hearty and wholesome Winter Menu. ... Breakfast Sandwich, Turkey Mash-Up Sandwich, Cranberry Crunch & Honey Parfait, Slow Cooked Smoky ...
(Date:1/16/2017)... , ... January 16, 2017 , ... California Southern University ... has served on CalSouthern’s Board of Trustees and as a core faculty member, teaching ... has been a professor of psychology at Pepperdine University, where he earned his Doctor ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... will demonstrate their groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs at the NSSF SHOT ... Las Vegas, Booth #2809. The SHOT Show is the shooting, hunting and outdoor ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... CHICAGO , Jan. 17, 2017 ... personalize cancer care, and University Hospitals Seidman Cancer ... healthcare by making genomic data, advanced molecular analysis ... hospital,s researchers, physicians and healthcare providers. ... will provide genomic and transcriptomic sequencing and analysis ...
(Date:1/17/2017)... , Jan. 17, 2017  ANI Pharmaceuticals, Inc. ... the appointment of Karen Quinn Ph.D as Vice ... Karen Quinn is ... experience in Global Regulatory Affairs, specifically with a ... ingredients.  Dr. Quinn worked most recently with Takeda ...
(Date:1/17/2017)... York , January 17, 2017 Transparency ... (Cinnamic Acid, Benzoic Acid, Sodium Benzoate, Benzyl Alcohol and Others) Market ... According to the report, the global benzaldehyde derivative market ... to reach US$ 2.14 Bn by 2024, expanding at a CAGR ... ...
Breaking Medicine Technology: